Howard H Lau, MD | |
2215 N Cascade Ave, Colorado Springs, CO 80907-6736 | |
(719) 776-5000 | |
(719) 448-0767 |
Full Name | Howard H Lau |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Experience | 27 Years |
Location | 2215 N Cascade Ave, Colorado Springs, Colorado |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053304915 | NPI | - | NPPES |
P00070239 | Other | CO | RAILROAD MEDICARE NUMBER |
96587067 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 41226 (Colorado) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Centura Health-penrose St Francis Health Services | Colorado springs, CO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Us Anesthesia Partners Of Colorado Inc | 6002072055 | 570 |
News Archive
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009.
An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).
Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.
› Verified 9 days ago
Entity Name | Us Anesthesia Partners Of Colorado Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1922365782 PECOS PAC ID: 6002072055 Enrollment ID: O20120725000032 |
News Archive
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009.
An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).
Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Howard H Lau, MD Po Box 820, Colorado Springs, CO 80901-0820 Ph: (719) 448-0981 | Howard H Lau, MD 2215 N Cascade Ave, Colorado Springs, CO 80907-6736 Ph: (719) 776-5000 |
News Archive
PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009.
An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).
Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.
› Verified 9 days ago
Dr. Lee Tan Wolfe, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 222 N Nevada Ave, Colorado Springs, CO 80907 Phone: 719-776-5142 Fax: 719-776-5827 | |
Christopher D Chinn, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4090 Briargate Pkwy, Colorado Springs, CO 80920 Phone: 720-777-1234 | |
Mr. Charles Herbert Ripp, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 8540 Scarborough Dr, Suite 370, Colorado Springs, CO 80920 Phone: 719-358-8270 Fax: 719-358-8299 | |
Russell Allen, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Boulder St, Colorado Springs, CO 80909 Phone: 719-365-6999 Fax: 719-365-2837 | |
Jennifer Kollman, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Boulder St, Colorado Springs, CO 80909 Phone: 719-365-6999 Fax: 719-365-2837 | |
Dr. Michael J Wempe, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 1615 Medical Center Pt, Colorado Springs, CO 80907 Phone: 719-544-1600 | |
Dr. Melissa Cary-jacobs Schmoekel, D.O Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Boulder St Ste 2508, Colorado Springs, CO 80909 Phone: 719-365-6999 Fax: 719-365-2837 |